Portal de Periódicos da CAPES

Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial

2023; BioMed Central; Volume: 14; Issue: 1 Linguagem: Inglês

10.1186/s13287-023-03402-8

1757-6512

Morteza Zarrabi, Mohammad Amin Shahrbaf, Masoumeh Nouri, Faezeh Shekari, Seyedeh-Esmat Hosseini, Seyed Mohammad Reza Hashemian, Rasoul Aliannejad, Hamidreza Jamaati, Naghmeh Khavandgar, Hediyeh Alemi, Hoda Madani, Abdoreza Nazari, Azadeh Amini, Seyedeh‐Nafiseh Hassani, Fatemeh Abbasi, Neda Jarooghi, Nader Fallah, Leila Taghiyar, Meysam Ganjibakhsh, Ensiyeh Hajizadeh‐Saffar, Massoud Vosough, Hossein Baharvand,

Long-Term Effects of COVID-19

The main causes of death in patients with severe Coronavirus disease-2019 (COVID-19) are acute respiratory distress syndrome (ARDS) and multiorgan failure caused by a severe inflammatory cascade. Novel treatment strategies, such as stem-cell-based therapy and their derivatives can be used to relieve inflammation in these cases. In this study, we aimed to evaluate the safety and efficacy of therapy using mesenchymal stromal cells (MSCs) and their derived extracellular vesicles in COVID-19 patients.